Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
Дата публикации: 19-10-2026 07:00:00

Evidence for efficacy is based on the results of the RASolute 302 study

Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Tumore al pancreas: primo sì dell'Europa al farmaco che raddoppia la sopravvivenza06.1717-10-2026
2FDA approves landmark pancreatic cancer drug that's shown to improve survival07.926-08-2026
3FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma09.1822-07-2026
4FDA approves groundbreaking new pancreatic cancer drug07.7726-08-2026
5FDA gives expedited approval to new groundbreaking pancreatic cancer drug06.4926-08-2026
6FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastro-oesophageal junction, or oesophageal adenocarcinoma03014-10-2026
7FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination with Pembrolizumab for First-Line Treatment of TNBC013.9905-08-2026
8Landmark NHS approval of cancer drugs offers new hope for children and adults with rare blood cancers011.7717-07-2026
9FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer016.5422-07-2026
10В России зарегистрировали препарат от агрессивной формы рака01019-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 13.78. Источник: www.esmo.org.